Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 ...

Evercore ISI launched its coverage with a bullish view on a number of biotech stocks on Tuesday, citing a more constructive view on the sector, which is seeing signs of recovery after years of ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Sanofi chief executive Paul Hudson began in sales jobs at groups including GSK. He now needs to draw heavily on ...

The high growth potential of biotech stocks brings many home-run-seeking investors to the Nasdaq Biotechnology Index. Collaboration with one of the world’s largest biotechs is the most compelling part ...

Dupilumab (Dupixient) can lead to sustained reductions in the need for oral corticosteroids (OCSs) for patients with severe asthma, and for some patients, it can eliminate the need for OCSs, as ...

As we’re seeing with the Russia-Ukraine war, getting world leaders to agree on diplomatic policy is a major challenge. On a far less critical scale, the same goes for sell-side research firms when it ...

RENSSELAER – Regeneron was on a roll coming out of 2021 but might lose some steam this year. The pharmaceutical developer (NASDAQ: REGN) reported a 104 percent increase in fourth-quarter revenues ...

For anyone who needed proof that a drugmaker is more than its most significant drug, just consider Regeneron (REGN). The company makes a COVID-19 treatment, but that's not what brought it down ...

DelveInsight's Peanut Allergy - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Peanut Allergy in the 7MM. Peanut ...

These pharmaceutical companies might make great long-term additions to your portfolio. Here's why you may want to take a look at these two companies. Still down from its all-time highs of $61 set back ...